The following is a summary of the Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Boston Scientific reported Q3 2024 revenue of $4,209 million, reflecting an organic growth of 18%, surpassing the expected range.

• Adjusted EPS for Q3 was $0.63, which indicates a growth of 27% from the prior period.

• Adjusted operating margin was disclosed at 27.2%, showing robust operational efficiency.

• Q3 adjusted gross margin was noted at 70.4%, slightly impacted by foreign exchange but demonstrating strong financial control.

Business Progress:

• The company is preparing for the commercial launch of FARAPULSE in Japan and anticipates meaningful global business impact in 2025.

• Boston Scientific is nearing the completion of the Axonics acquisition, slated to close in Q4 2024, expected to strengthen the Urology business significantly.

• Introduced the next-generation ACURATE Prime Valve in TAVI and noted continued above-market growth in its cardiology division.

• Announced strategic changes in leadership within the EMEA region, affirming its commitment to global market expansion and internal growth.

Opportunities:

• Significant market expansion opportunities identified with the upcoming commercial launches of FARAPULSE in Japan and China, alongside expected continual growth from the Axonics integration.

• Regulatory advancements in cardiology, specifically the recent CE approvals and impending studies, bolster potential for wider adoption and market penetration in structural heart and EP solutions.

Risks:

• No explicit risks mentioned

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.